Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 15/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5410979 | 1.00 | OPRL1 (0.39) | OPRL1OPRM1OPRK1C5AR1EGLN1 | |
| SCHEMBL4976432 | 0.91 | OPRL1 (0.39) | OPRL1OPRM1OPRK1 | |
| SCHEMBL4976435 | 0.91 | OPRL1 (0.39) | OPRL1OPRM1OPRK1 | |
| SCHEMBL4976408 | 0.91 | OPRL1 (0.42) | OPRL1OPRM1OPRK1 | |
| SCHEMBL4976410 | 0.91 | OPRL1 (0.42) | OPRL1OPRM1OPRK1 | |
| SCHEMBL4976332 | 0.85 | OPRL1 (0.34) | OPRL1 | |
| SCHEMBL4976339 | 0.85 | OPRL1 (0.32) | OPRL1OPRM1OPRK1 | |
| SCHEMBL4976403 | 0.85 | OPRL1 (0.46) | OPRL1OPRM1OPRK1C5AR1EGLN1 | |
| SCHEMBL4976407 | 0.85 | OPRL1 (0.46) | OPRL1OPRM1OPRK1C5AR1EGLN1 | |
| SCHEMBL4981062 | 0.84 | OPRL1 (0.36) | OPRL1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279486-B2 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER JAPAN INC. (JP) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | OPRL1, OGFRL1, ORMDL3 | OPRL1 1/4885OPRM1 7/4885OPRK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.